Please assess the completion status of the following clinical trial:

Trial Title: Treatment Protocols for Patients With Symptomatic Oral Lichen Planus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≥ 18 years;~* clinical diagnosis and histological diagnosis of OLP on the basis of WHO criteria;~* presence of symptoms related to OLP.~Exclusion Criteria:~* presence of systemic conditions that may have affected the study results;~* state of pregnancy or breastfeeding;~* histological signs of dysplasia;~* drugs inducing a lichen response (ACE-inhibitors, β-blockers, etc.);~* treatment of OLP in the six months prior to the start of the programme;~* presence of extraoral lesions (genital, skin and other)~* history of previous immunodeficiency or HIV seropositivity;~* previous allogeneic bone marrow transplantation;~* presence of systemic lupus erythematosus or other autoimmune diseases.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Clobetasol treatment (Type: ACTIVE_COMPARATOR): The clobetasol group was treated with clobetasol propionate 0.05%, while the anti-inflammatory group was treated with mouthwash. The drug used consisted of Clobetasol propionate 0.05%, Ethyl alcohol 96° (50%), Hydroxyethylcellulose (4%); Preserved water (just enough to 100%) that was topically applied \[11\]. This drug was produced as a galenic formulation. Clobetasol propionate twice a day (every 12 hours) to the lesions with a soft bristle brush and were advised not to drink or eat during the hour following application of the medication.
- Anti-inflammatory mouthwash (Type: ACTIVE_COMPARATOR): In patients of the anti-inflammatory group, the mouthwash was used pure and without dilution at a dosage of 20 ml 3 times a day, immediately after normal daily oral hygiene was prescribed. It contains calcium hydroxide, hyaluronic acid, Umbelliferone and Oligomeric Proanthocyanidins. Patients were instructed to rinse for at least 5 minutes over the entire oral mucosa, with particular emphasis on the regions where the lesions are located.

Based on this trial design, predict the completion outcome and termination type (if applicable).